InProTher is a biotechnology company developing ground-breaking immunotherapies to fight and treat cancer. In late 2021, Innovayt helped InProTher secure €9.1 million from the EIC Accelerator programme, which allows them to fully develop their technology and bring the first broad cancer vaccine to market.

Secured in total €2.7 million in grant from the MSCA Doctoral Network programme to implement the BiodeCCodiNNg project, with the main goal to train 10 Ph.D. students with out-of-the-box thinking and an entrepreneurial mindset to expand the repertoire of enzymes for industrial biotechnology.

Pioneering stem cell treatment for chronic diseases, using Blue Cells to reverse Erectile Dysfunction. Secured EUROSTARS and InnoBooster grants to develop autologous and allogeneic treatments, respectively.

Novel software solution for the financial sector for automating compliance with EU’s GDPR.

Improving EU success rates of Norwegian SMEs.

EU funding for advanced 3D imaging of materials.

Funding from the Research Council of Norway to support preclinical trials of new chemotherapeutic agents.

Ground-breaking technology to bond dissimilar materials based on specifically designed polymer brushes.

Automation of medical image analysis.

EU grant for 14 young biotech researchers at the Technical University of Denmark.

Facilitating EU funding for Central Denmark

High power storage systems.

Developing a black box for autonomous marine vessels.